Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with “highest risk” RET mutation

• Published in: Stem cell research Vol. 23; no. C; pp. 154 - 157
• Main Authors: Bennaceur-Griscelli, A., Hadoux, J., Féraud, O., Opolon, P., Divers, D., Gobbo, E., Schlumberger, M., Griscelli, F., Turhan, A.G.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.08.2017; Elsevier
• Subjects: Cell Culture Techniques - methods; Cell Line; Humans; Induced Pluripotent Stem Cells - pathology; Multiple Endocrine Neoplasia Type 2b - genetics; Multiple Endocrine Neoplasia Type 2b - pathology; Mutation - genetics; Proto-Oncogene Proteins c-ret - genetics; Risk Factors; Young Adult
• ISSN: 1873-5061; 1876-7753
• DOI: 10.1016/j.scr.2017.07.022

Multiple Endocrine Neoplasia Type 2B (MEN2B) is a cancer-predisposing syndrome that affects patients with germline RET mutations. The clinical spectrum of the syndrome includes medullary thyroid carcinoma (MTC) and pheochromocytoma. Currently, there is no satisfactory model recapitulating all the features of the disease especially at the level of stem cells. We generated induced pluripotent stem cells (iPSCs) from a patient with RET mutation at codon 918 who developed pheochromocytoma and MTC. These iPSC had normal karyotype, harboured the RETM918T mutation and expressed pluripotency hallmarks. A comprehensive pathological assessment of teratoma was performed after injection in immunodeficient mice.